External beam radiotherapy for synchronous rectal and prostatic tumors.
Two patients were diagnosed with large rectal tumors and localized prostate cancer. The prostate-specific antigen level at diagnosis was 7.9 ng/mL and 9.0 ng/mL in the 2 patients. Knowledge of the presence of both tumors and their close proximity allowed creation of a modified three-dimensional conformal radiotherapy plan to treat both tumors. The patients had no evidence of rectal tumor recurrence and their prostate-specific antigen level was 0.5 ng/mL and 0.7 ng/mL at 1 and 2 years after therapy, respectively. We conclude that efficient, effective pelvic irradiation can be designed for synchronous rectal and prostate malignancies.
Siu
W
W
Department of Urology, Stanford University Medical Center, Stanford, California, USA.
Kapp
D S
DS
Wren
S M
SM
King
C
C
Terris
M K
MK
D000230:Adenocarcinoma / Q000532:radiotherapy; D000368:Aged; D017024:Chemotherapy, Adjuvant; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D012004:Rectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D012074:Remission Induction
D017430:Prostate-Specific Antigen; D005472:Fluorouracil